Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea flag South Korea · Delayed Price · Currency is KRW
21,650
-50 (-0.23%)
Last updated: Sep 9, 2025, 2:22 PM KST

Ildong Pharmaceutical Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2020
668,619328,764502,483764,721799,187449,542
Upgrade
Market Cap Growth
-3.31%-34.57%-34.29%-4.31%77.78%18.46%
Upgrade
Enterprise Value
812,400467,886480,579872,139869,595531,687
Upgrade
Last Close Price
21650.0011770.0018160.0028550.0033600.0018900.00
Upgrade
Forward PE
-14.7614.7614.7614.7614.76
Upgrade
PS Ratio
1.140.540.841.201.430.80
Upgrade
PB Ratio
3.991.982.803.754.791.77
Upgrade
P/TBV Ratio
4.902.483.754.967.372.08
Upgrade
P/FCF Ratio
100.8918.67---89.66
Upgrade
P/OCF Ratio
41.1911.62---23.21
Upgrade
PEG Ratio
-0.320.320.320.320.32
Upgrade
EV/Sales Ratio
1.390.760.801.371.550.95
Upgrade
EV/EBITDA Ratio
20.3612.52---16.02
Upgrade
EV/EBIT Ratio
52.9540.93---96.16
Upgrade
EV/FCF Ratio
122.5926.56---106.04
Upgrade
Debt / Equity Ratio
1.241.241.191.021.360.66
Upgrade
Debt / EBITDA Ratio
5.185.50---5.03
Upgrade
Debt / FCF Ratio
31.4011.67---33.28
Upgrade
Asset Turnover
0.991.020.950.940.850.92
Upgrade
Inventory Turnover
3.804.424.234.443.974.07
Upgrade
Quick Ratio
0.400.520.410.440.590.74
Upgrade
Current Ratio
0.790.920.690.910.841.26
Upgrade
Return on Equity (ROE)
-5.73%-7.17%-42.25%-76.68%-47.91%-5.13%
Upgrade
Return on Assets (ROA)
1.64%1.19%-5.27%-6.75%-5.17%0.57%
Upgrade
Return on Capital (ROIC)
2.55%1.87%-8.31%-11.44%-8.35%0.82%
Upgrade
Return on Capital Employed (ROCE)
5.70%3.60%---1.30%
Upgrade
Earnings Yield
-0.37%-1.39%-15.71%-18.52%-12.48%-2.90%
Upgrade
FCF Yield
0.99%5.36%-9.91%-8.55%-3.25%1.11%
Upgrade
Buyback Yield / Dilution
-1.19%-3.34%-2.61%-10.76%0.00%0.02%
Upgrade
Total Shareholder Return
--3.34%-2.61%-10.76%0.00%0.02%
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.